Skip to content Skip to main navigation

Our Story

The Canadian MPN Group was founded by hematologists working in the field of MPNs as the first national collaborative effort between health professionals in Canada to improve MPN patient care and research.

The beginnings of the Canadian MPN Group lie in a discussion at a hematology meeting between several of our now National Executives on MPN patient care and research in Canada.  Their discussion led them to the topic of the then current lack of a collaborative physician-driven MPN organization in Canada and the benefits it would bring to improve the care of MPN patients.

Since this meeting in 2011 the generous support of Mr Ed Pascal has enabled us to establish the Canadian MPN Group as a national charitable organization in 2013 and we have, with support from our donors, pursued our mission of improving MPN research and care of patients with MPNs.

Mission Statement: To improve the care and research in patients with myeloproliferative neoplasms (MPN) through inter-professional collaboration.

In the few short years since our establishment, the Canadian MPN Group has contributed to physician education with our publications on MPN treatment guidelines1,2 and our network of MPN physicians is continuing to expand, benefiting both patient care and research collaboration.  With these and our ongoing efforts in MPN care, research and professional collaboration, we continue to work towards our ultimate goal of comprehensive access to good quality care for Canadians with MPNs.

We thank all of supporters.  We are deeply grateful for all of our many funders, without whom the Canadian MPN Group would not be possible.  Our thanks in particular go to Mr. Ed Pascal for his support in establishing the Canadian MPN Group and to Mr. Tony Comper for funding the current version of this website. We also thank Novartis for their support, including for the development of the MPN eSIMPLE app.


1 Gupta V, Foltz L, Sirhan S, Busque L, Turner RA. Emerging therapeutic options for myelofibrosis: a Canadian perspective. 2012; 2(3): 170-186.

2 Sirhan S, Busque L, Foltz L, Grewal K, Hamm C, Laferriere N, Laneuville P, Leber B, Liew E, Olney HJ, Prchal J, Porwit A, Gupta V. Evolving Therapeutic Options for Polycythemia Vera: Perspectives of the Canadian Myeloproliferative Neoplasms (MPN) Group. 2015. Clinical Lymphoma, Myeloma and Leukemia. 2015; 15(12):715-727.

Stay up to date

Read the Canadian MPN Group newsletter for the latest in the field.

Watch Dr Vikas Gupta speak about Stem Cell Transplant for Myelofibrosis in the JAK2 Inhibitor Era.

Download the new MPN eSimple app.

We need your help

The Canadian MPN Group relies on donor contributions to keep our work going. Can you help?

Twitter Feed